Literature DB >> 26205218

Prediction of Diabetes Remission in Morbidly Obese Patients After Roux-en-Y Gastric Bypass.

Ji Yeon Park1,2, Yong Jin Kim3.   

Abstract

BACKGROUND: Morbidly obese patients with type 2 diabetes have shown significant improvement in glycemic control after Roux-en-Y gastric bypass (RYGB). This study aimed to elucidate the predictors of diabetes remission.
METHODS: A retrospective review of a prospectively established database identified 134 type 2 diabetes patients who underwent laparoscopic RYGB between January 2011 and February 2014. Partial and complete remission of diabetes was defined as glycated hemoglobin (HbA1c) level <6.5 and <6.0%, respectively, without the use of antidiabetic medication. Pre- and postoperative clinical outcomes were compared between the remission and non-remission groups to identify the predictors of partial or complete remission of diabetes.
RESULTS: The mean duration of diabetes and preoperative HbA1c level were 4.6 years and 8.0%, respectively. The body mass index (BMI) of the enrolled patients decreased from 37.9 to 28.8 kg/m(2) during the mean follow-up of 12.3 months; 61.8% of the patients achieved partial or complete remission of diabetes. Multivariate analysis revealed that age at operation (odds ratio [OR] = 0.880; 95% confidence interval [CI] 0.807-0.960), HbA1c level (OR = 0.527; 95% CI 0.325-0.854), and C-peptide level (OR = 1.463; 95% CI 1.054-2.029) in the preoperative laboratory study, and the percentage of total weight loss (%TWL) (OR = 1.186; 95% CI 1.072-1.313) after RYGB were the independent predictors of partial or complete diabetes remission.
CONCLUSION: The predictive factors for diabetes remission after RYGB include age at operation, HbA1c and C-peptide levels, and the %TWL after surgery.

Entities:  

Keywords:  Diabetes remission; Morbid obesity; Roux-en-Y gastric bypass; Type 2 diabetes

Mesh:

Year:  2016        PMID: 26205218     DOI: 10.1007/s11695-015-1823-3

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  31 in total

Review 1.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

Review 2.  The role of gut hormones in glucose homeostasis.

Authors:  Daniel J Drucker
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

3.  IFSO-APC consensus statements 2011.

Authors:  Kazunori Kasama; Wilfred Mui; Wei Jei Lee; Muffazal Lakdawala; Takeshi Naitoh; Yosuke Seki; Akira Sasaki; Go Wakabayashi; Iwao Sasaki; Isao Kawamura; Lilian Kow; Harry Frydenberg; Anton Chen; Mahendra Narwaria; Pradeep Chowbey
Journal:  Obes Surg       Date:  2012-05       Impact factor: 4.129

4.  Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity.

Authors:  Tom C Hall; Mike G C Pellen; Peter C Sedman; Prashant K Jain
Journal:  Obes Surg       Date:  2010-09       Impact factor: 4.129

5.  Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes.

Authors:  Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap
Journal:  N Engl J Med       Date:  2014-03-31       Impact factor: 91.245

6.  Insulin sensitivity and secretion changes after gastric bypass in normotolerant and diabetic obese subjects.

Authors:  Serenella Salinari; Alessandro Bertuzzi; Caterina Guidone; Elena Previti; Francesco Rubino; Geltrude Mingrone
Journal:  Ann Surg       Date:  2013-03       Impact factor: 12.969

7.  How do we define cure of diabetes?

Authors:  John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

8.  Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity.

Authors:  Ricardo V Cohen; Jose C Pinheiro; Carlos A Schiavon; João E Salles; Bernardo L Wajchenberg; David E Cummings
Journal:  Diabetes Care       Date:  2012-07       Impact factor: 19.112

9.  Clinical experience of weight loss surgery in morbidly obese Korean adolescents.

Authors:  Ji Yeon Park; Dan Song; Yong Jin Kim
Journal:  Yonsei Med J       Date:  2014-09       Impact factor: 2.759

10.  Adults with long-duration type 2 diabetes have blunted glycemic and β-cell function improvements after bariatric surgery.

Authors:  Vishesh Khanna; Steven K Malin; James Bena; Beth Abood; Claire E Pothier; Deepak L Bhatt; Steven Nissen; Richard Watanabe; Stacy A Brethauer; Philip R Schauer; John P Kirwan; Sangeeta R Kashyap
Journal:  Obesity (Silver Spring)       Date:  2015-02-03       Impact factor: 5.002

View more
  15 in total

1.  Preoperative Beta Cell Function Is Predictive of Diabetes Remission After Bariatric Surgery.

Authors:  Pedro Souteiro; Sandra Belo; João Sérgio Neves; Daniela Magalhães; Rita Bettencourt Silva; Sofia Castro Oliveira; Maria Manuel Costa; Ana Saavedra; Joana Oliveira; Filipe Cunha; Eva Lau; César Esteves; Paula Freitas; Ana Varela; Joana Queirós; Davide Carvalho
Journal:  Obes Surg       Date:  2017-02       Impact factor: 4.129

2.  Reply to the Comment on: "Prediction of Diabetes Remission in Morbidly Obese Patients After Roux-en-Y Gastric Bypass".

Authors:  Ji Yeon Park; Yong Jin Kim
Journal:  Obes Surg       Date:  2016-12       Impact factor: 4.129

3.  Comment on: "Prediction of Diabetes Remission in Morbidly Obese Patients After Roux-en-Y Gastric Bypass."

Authors:  Pulimuttil James Zachariah; Wei-Jei Lee
Journal:  Obes Surg       Date:  2016-12       Impact factor: 4.129

4.  Prediction of Long-Term Diabetes Remission After Metabolic Surgery in Obese East Asian Patients: a Comparison Between ABCD and IMS Scores.

Authors:  Masayuki Ohta; Yosuke Seki; Tetsuji Ohyama; Rixing Bai; Sang Hyun Kim; Takashi Oshiro; Tao Jiang; Akira Sasaki; Takeshi Naitoh; Tsuyoshi Yamaguchi; Susumu Inamine; Yasuhiro Miyazaki; Soo Min Ahn; Yoonseok Heo; Hui Liang; Seung Ho Choi; Wah Yang; Qiyuan Yao; Kentaro Inoue; Hiroshi Yamamoto; Hyuk-Joon Lee; Young Suk Park; Tae Kyung Ha; Seung-Wan Ryu; Cunchuan Wang; Sungsoo Park; Kazunori Kasama
Journal:  Obes Surg       Date:  2021-01-07       Impact factor: 4.129

5.  Type 2 diabetes remission following gastric bypass: does diarem stand the test of time?

Authors:  J Hunter Mehaffey; Mathew G Mullen; Rachel L Mehaffey; Florence E Turrentine; Steven K Malin; Jennifer L Kirby; Bruce Schirmer; Peter T Hallowell
Journal:  Surg Endosc       Date:  2016-05-13       Impact factor: 4.584

6.  Laparoscopic Magenstrasse and Mill Gastroplasty (M&M): Midterm Results.

Authors:  Maud Neuberg; Pierre-Arnaud Wuidar; Laurent Kohnen; Jenny Deflines; Nikos Kotzampassakis; Martine Demarche; Arnaud De Roover
Journal:  Obes Surg       Date:  2019-10       Impact factor: 4.129

7.  Validation of Ad-DiaRem and ABCD Diabetes Remission Prediction Scores at 1-Year After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy in the Randomized Controlled Oseberg Trial.

Authors:  Farhat Fatima; Jøran Hjelmesæth; Jens Kristoffer Hertel; Marius Svanevik; Rune Sandbu; Milada Cvancarova Småstuen; Dag Hofsø
Journal:  Obes Surg       Date:  2022-01-04       Impact factor: 4.129

8.  Gastric bypass procedure for type 2 diabetes patients with BMI <28 kg/m2.

Authors:  Ke Gong; Kai Li; Nengwei Zhang; Bin Zhu; Dexiao Du; Dongdong Zhang; Zhen Zhang; Jirun Peng
Journal:  Surg Endosc       Date:  2016-07-15       Impact factor: 4.584

9.  Validating Risk Prediction Models of Diabetes Remission After Sleeve Gastrectomy.

Authors:  Shih-Chiang Shen; Weu Wang; Ka-Wai Tam; Hsin-An Chen; Yen-Kuang Lin; Shih-Yun Wang; Ming-Te Huang; Yen-Hao Su
Journal:  Obes Surg       Date:  2019-01       Impact factor: 4.129

Review 10.  Bariatric surgery for the management of type 2 diabetes mellitus-current trends and challenges: a review article.

Authors:  Mansur Suliman Alqunai; Fauwaz Fahad Alrashid
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.